The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

They could perhaps see sustained runs beyond this year.

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

And, if all goes well, over the next five years as well.

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

A life sciences hub in Syracuse is getting a major upgrade as New York pushes to grow its biotechnology sector. Gov. Kathy ...

Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.

Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company ...

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...